BR0309809A - indução de toleráncia imunológica especìfica quanto ao antìgeno - Google Patents

indução de toleráncia imunológica especìfica quanto ao antìgeno

Info

Publication number
BR0309809A
BR0309809A BRPI0309809-5A BR0309809A BR0309809A BR 0309809 A BR0309809 A BR 0309809A BR 0309809 A BR0309809 A BR 0309809A BR 0309809 A BR0309809 A BR 0309809A
Authority
BR
Brazil
Prior art keywords
toleragen
antigen
induction
immunological tolerance
specific immune
Prior art date
Application number
BRPI0309809-5A
Other languages
English (en)
Inventor
Emil D Kakkis
Merry Passage
Thomas Lester
Rebecca Yang
Christopher Tanaka
Original Assignee
Biomarin Pharm Inc
Harbor Ucla Res & Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc, Harbor Ucla Res & Education filed Critical Biomarin Pharm Inc
Publication of BR0309809A publication Critical patent/BR0309809A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"INDUçãO DE TOLERáNCIA IMUNOLóGICA ESPECìFICA QUANTO AO ANTìGENO". Tolerância imune específica quanto ao antígeno é induzida em um hospedeiro mamífero por administração de um tolerágeno em combinação com um regime de imunossupressão. Os métodos opcionalmente incluem um período de condicionamento precedente, em que agentes imunossupressores são administrados na ausência do tolerágeno. Depois do regime tolerizantes, o hospedeiro é retirado dos agentes supressores, mas é capaz de manter tolerância imune específica com relação aos epítopos imunogênicos presentes no tolerágeno. Opcionalmente, o tolerágeno terá propriedades de elevada assimilação, que permitem assimilação in vivo em baixas concentrações, em uma ampla variedade de tipos de células tolerizantes.
BRPI0309809-5A 2002-05-06 2003-05-05 indução de toleráncia imunológica especìfica quanto ao antìgeno BR0309809A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/141,668 US7485314B2 (en) 2002-05-06 2002-05-06 Induction of antigen specific immunologic tolerance
PCT/US2003/013843 WO2003094840A2 (en) 2002-05-06 2003-05-05 Induction of antigen specific immunologic tolerance

Publications (1)

Publication Number Publication Date
BR0309809A true BR0309809A (pt) 2007-01-09

Family

ID=29399718

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309809-5A BR0309809A (pt) 2002-05-06 2003-05-05 indução de toleráncia imunológica especìfica quanto ao antìgeno

Country Status (16)

Country Link
US (3) US7485314B2 (pt)
EP (1) EP1507555B1 (pt)
JP (1) JP4933042B2 (pt)
CN (1) CN100360182C (pt)
AR (1) AR039882A1 (pt)
AU (1) AU2003228829B2 (pt)
BR (1) BR0309809A (pt)
CA (1) CA2492394A1 (pt)
ES (1) ES2401681T3 (pt)
HK (1) HK1081438A1 (pt)
IL (1) IL165016A (pt)
MX (1) MXPA04009292A (pt)
TW (1) TWI349556B (pt)
UY (1) UY27795A1 (pt)
WO (1) WO2003094840A2 (pt)
ZA (1) ZA200409787B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
JP2008521907A (ja) * 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
AU2006209837A1 (en) * 2005-02-04 2006-08-10 Dow Agrosciences, Llc Anti-T cell and autoantigen treatment of autoimmune disease
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
JP2010524849A (ja) * 2007-03-21 2010-07-22 ラプトール ファーマシューティカル インコーポレイテッド 環状受容体関連蛋白ペプチド
HUE034850T2 (en) 2008-05-07 2018-03-28 Biomarin Pharm Inc Lysosomal targeting peptides and their use
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP2493487B1 (en) * 2009-10-27 2016-08-24 Erytech Pharma Composition to induce specific immune tolerance
PT2632479T (pt) * 2010-10-27 2017-07-24 Baxalta Inc Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico
CA2834532A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
CA2835819A1 (en) * 2011-05-16 2012-11-22 Genzyme Corporation Induction of immune tolerance using methotrexate
EA029560B1 (ru) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
JP2015511628A (ja) * 2012-04-02 2015-04-20 ユニバーシティ オブ ブリストル 寛容化誘導組成物
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
LT3115372T (lt) 2012-11-27 2019-06-25 Biomarin Pharmaceutical Inc. Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas
KR20220025908A (ko) 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. 제i형 및 제iv형 과민성을 감소시키기 위한 관용유발 합성 나노담체의 국부, 병용 투여
KR20240093939A (ko) * 2013-05-15 2024-06-24 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
EP3189147A1 (en) 2014-09-07 2017-07-12 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2017079729A1 (en) 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
BR112018071156A2 (pt) 2016-04-15 2019-03-12 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
JPWO2019245038A1 (ja) * 2018-06-22 2021-07-08 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
CN113301925A (zh) 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
DK0572478T3 (da) 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
CA2129351A1 (en) * 1992-02-10 1993-08-19 Barton F. Haynes Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens
US5747034A (en) 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
WO1996023882A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
JP2001511187A (ja) 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20050191309A1 (en) * 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance

Also Published As

Publication number Publication date
AR039882A1 (es) 2005-03-09
US20030211113A1 (en) 2003-11-13
HK1081438A1 (en) 2006-05-19
AU2003228829A1 (en) 2003-11-11
EP1507555B1 (en) 2012-12-19
TW200400045A (en) 2004-01-01
US7485314B2 (en) 2009-02-03
CA2492394A1 (en) 2003-11-20
CN100360182C (zh) 2008-01-09
ZA200409787B (en) 2006-07-26
JP2005530762A (ja) 2005-10-13
IL165016A0 (en) 2005-12-18
US20090238818A1 (en) 2009-09-24
ES2401681T3 (es) 2013-04-23
JP4933042B2 (ja) 2012-05-16
EP1507555A4 (en) 2009-07-15
MXPA04009292A (es) 2005-06-08
WO2003094840A2 (en) 2003-11-20
US7883707B2 (en) 2011-02-08
IL165016A (en) 2012-01-31
EP1507555A2 (en) 2005-02-23
AU2003228829B2 (en) 2009-05-21
UY27795A1 (es) 2003-11-28
TWI349556B (en) 2011-10-01
US20040009906A1 (en) 2004-01-15
WO2003094840A3 (en) 2004-03-11
CN1652814A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
BR0309809A (pt) indução de toleráncia imunológica especìfica quanto ao antìgeno
CY1123299T1 (el) Ανοσοενισχυτικη μηνιγκιτιδοκοκκικη πρωτεϊνη προσδεσης παραγοντα η
BR0014386A (pt) Composição
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
BR112013021871A2 (pt) lentes de contato de silicone hidrogel com níveis aceitáveis de perda de energia
BR0208207A (pt) Redução da imunogenicidade das proteìnas de fusão
BR0109158A (pt) Cepa alterada do vìrus de varìola bovina de ankara (mva)
BR0207854A (pt) Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
Gonzalez et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
BR0108386C1 (pt) urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
BR9908424A (pt) Processo para purificar uma preparação de herpesvìrus
Forsum et al. Distribution of Ia‐antigen‐like molecules on non‐lymphoid tissues
BR0312474A (pt) Partìcula viral adjuvante
Jahanian et al. Marginal deficiencies of dietary arginine and methionine could suppress growth performance and immunological responses in broiler chickens
BR0309963A (pt) Proteìna de fusão das proteìnas reguladoras/acessórias do hiv
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
BR0215588A (pt) Compostos imunoefetores
WO2006052668A3 (en) Induction of antigen specific immunologic tolerance
TR200100948T2 (tr) Cinsel yoldan bulaşan hastalıklara karşı aşı
BR0008645A (pt) Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição
BR112023002724A2 (pt) Neoantígenos ras e seus usos

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE REIVINDICADA (US10/141,668) POR NAO ATENDER A DISPOSICAO PREVISTA NO ART.16 6O E 7O DA LPI.

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: ANULADA A PERDA DE PRIORIDADE(15.9) PUBLICADA NA RPI 2011 POR TER SIDO INDEVIDA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.